These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8197924)

  • 1. Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up.
    Minervini R; Cecchi M; Felipetto R; Viganò L; Pagni G
    Acta Urol Belg; 1994 Apr; 62(1):1-5. PubMed ID: 8197924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.
    Minervini R; Felipetto R; Viganò L; Cecchi M
    Int Urol Nephrol; 1994; 26(4):437-42. PubMed ID: 8002217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
    Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
    Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
    Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
    Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
    Soloway MS
    Prog Clin Biol Res; 1990; 350():71-9. PubMed ID: 2117289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of superficial bladder cancer in a community setting.
    Haas JA
    Urology; 1985 Oct; 26(4 Suppl):51-4. PubMed ID: 3931328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical chemotherapy for superficial carcinoma of the bladder.
    Foo KT; Tan EC; Tung KH; Tock EP
    Singapore Med J; 1991 Dec; 32(6):420-2. PubMed ID: 1788600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
    Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A
    Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.